Tiova Inhaler: Advanced COPD Symptom Control and Bronchodilation
| Product dosage: 200 MD | |||
|---|---|---|---|
| Package (num) | Per inhaler | Price | Buy |
| 6 | $12.72 | $76.30 (0%) | 🛒 Add to cart |
| 10 | $9.54
Best per inhaler | $127.17 $95.38 (25%) | 🛒 Add to cart |
The Tiova Inhaler (Tiotropium Bromide) is a long-acting muscarinic antagonist (LAMA) inhaler prescribed for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It functions by relaxing the muscles around the airways, leading to significantly improved breathing for up to 24 hours after a single dose. This medication is a cornerstone in the management of stable COPD, aimed at reducing exacerbation frequency, improving exercise tolerance, and enhancing overall quality of life. It is not indicated for the initial relief of acute bronchospasm.
Features
- Active Pharmaceutical Ingredient: Tiotropium Bromide (18 mcg per inhalation).
- Device Type: Pressurized Metered-Dose Inhaler (pMDI) with a dose counter.
- Mechanism of Action: Long-acting muscarinic antagonist (LAMA).
- Duration of Effect: Provides sustained bronchodilation for 24 hours.
- Formulation: Dry powder for inhalation (in a capsule-based device for some variants; confirm device type with prescription).
- Prescription Status: Available by prescription only.
Benefits
- Sustained 24-Hour Bronchodilation: Ensures round-the-clock airway openness, reducing breathlessness during daily activities and through the night.
- Reduces COPD Exacerbation Frequency: Regular use is clinically proven to decrease the rate of moderate-to-severe flare-ups, which are associated with disease progression and hospitalizations.
- Improves Exercise Tolerance and Lung Function: By significantly increasing FEV1 (Forced Expiratory Volume in 1 second), it allows patients to engage in physical activity with less dyspnea.
- Enhances Quality of Life: Effective symptom control leads to greater independence, reduced reliance on rescue inhalers, and improved overall well-being.
- Complementary to Other Therapies: Can be used concomitantly with short-acting bronchodilators and inhaled corticosteroids as part of a comprehensive COPD management plan.
Common use
The Tiova Inhaler is primarily used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD). It is a controller medication, not a rescue inhaler. Its use is central to preventing and chronicling symptoms such as wheezing, shortness of breath (dyspnea), and chest tightness. It is a standard therapy for patients with moderate to severe COPD to improve lung function and reduce the impact of the disease on daily life.
Dosage and direction
The recommended dosage for the Tiova Inhaler is the inhalation of the contents of one capsule (18 mcg) once daily, at the same time each day, using the specific inhaler device provided.
Directions for Use (General Guide; always follow device-specific instructions):
- Ensure hands and the device are clean and dry.
- Open the device by lifting the mouthpiece cover.
- Remove a capsule from the blister pack immediately before use and place it in the chamber at the base of the device. Do not place the capsule in the mouthpiece.
- Close the device firmly until a click is heard, which pierces the capsule.
- Breathe out fully, away from the device. Do not exhale into the inhaler.
- Place the mouthpiece between your lips and breathe in deeply and steadily at a rate sufficient to hear the capsule vibrate. Hold your breath for up to 10 seconds, or as long as is comfortable.
- Remove the inhaler from your mouth and exhale slowly.
- Open the device to check if any powder remains. If powder remains, close the device and take a second inhalation.
- After use, discard the empty capsule and close the mouthpiece cover.
Crucial Note: The device must be kept dry at all times. Never wash the device. Wipe the mouthpiece with a dry cloth if needed.
Precautions
- Paradoxical Bronchospasm: Can occur immediately after inhalation, presenting as coughing, wheezing, and shortness of breath. Discontinue use immediately and institute alternative therapy if this occurs.
- Pre-existing Conditions: Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, moderate to severe renal impairment, or known hypersensitivity to atropine or its derivatives.
- Immediate Hypersensitivity Reactions: May occur, as evidenced by urticaria, angioedema, rash, and bronchospasm. Discontinue if such a reaction occurs.
- Eye Care: Advise patients to avoid getting the powder into their eyes, as it may cause blurring of vision and pupil dilation (mydriasis) or precipitate or aggravate narrow-angle glaucoma.
- Pregnancy and Lactation: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether tiotropium is excreted in human milk; caution should be exercised if administered to a nursing woman.
Contraindications
The Tiova Inhaler is contraindicated in patients with a history of hypersensitivity to tiotropium bromide, atropine or its derivatives, including ipratropium, or any other component of the product.
Possible side effect
The most common side effects are dry mouth and constipation. Other reported side effects include:
- Upper respiratory tract infection
- Pharyngitis
- Sinusitis
- Non-specific chest pain
- Urinary retention (especially in patients with pre-existing prostatic hyperplasia)
- Tachycardia (increased heart rate)
- Glaucoma (if powder comes into contact with eyes)
- Cough
- Dyspepsia
- Dizziness
- Hoarseness
Drug interaction
Formal drug interaction studies have not been performed with Tiova. However, due to its anticholinergic properties, Tiova should be used with caution when co-administered with other anticholinergic-containing drugs (e.g., ipratropium, aclidinium, glycopyrrolate) as this may potentiate adverse effects. It is frequently used concomitantly with sympathomimetic bronchodilators, methylxanthines, and oral or inhaled steroids without expected clinical interactions.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is too late on the same day, the missed dose should be skipped, and the next dose should be taken at the regular time the following day. Do not double the dose to make up for a missed one.
Overdose
An overdose is unlikely due to the low systemic absorption via the inhaled route. However, an overdose of anticholinergic agents may lead to effects such as dry mouth, visual accommodation disturbances, tachycardia, urinary retention, and constipation. Severe overdose could potentially lead to delirium, psychosis, and seizures. Treatment should be symptomatic and supportive.
Storage
- Store at room temperature (15°C to 30°C).
- Protect from moisture and heat. Keep the capsules in the blister pack and only remove immediately before use.
- Keep the device clean and dry; never wash any part of it.
- Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As a pulmonologist with over 20 years of experience, Tiova (tiotropium) remains a first-line foundational therapy in my COPD management strategy. Its once-daily dosing promotes excellent adherence, and the 24-hour efficacy provides patients with consistent symptom control, which is critical for slowing functional decline.” – Dr. E. Vance, MD, Pulmonology.
- “The transition from a SABA to Tiova for my maintenance therapy was life-changing. The constant tightness in my chest is gone, and I can now take my morning walk without having to stop every few minutes to catch my breath. The dry mouth is a minor inconvenience for the freedom it gives me.” – Michael T., patient for 3 years.
- “From a clinical trial perspective, the data for tiotropium is robust and undeniable. Its impact on reducing exacerbation rates is a key metric that directly correlates with improved long-term outcomes and reduced healthcare utilization in the COPD population.” – Clinical Research Associate.
- “I found the inhaler device easy to use after the pharmacist showed me the correct technique. The dose counter is a helpful feature that prevents me from running out unexpectedly. It has significantly reduced my reliance on my rescue inhaler.” – Sarah L., patient for 18 months.
- “While effective, it is imperative that prescribers thoroughly educate patients on the proper inhalation technique. Device mishandling is the primary cause of perceived treatment failure. The warning regarding eye exposure is also not to be taken lightly.” – Respiratory Therapist.